Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02511405
Title A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Vascular Biogenics Ltd. operating as VBL Therapeutics
Indications

glioblastoma

Therapies

Bevacizumab

VB-111

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.